NEW YORK, Feb. 6 (GenomeWeb News) - Lakeland Regional Cancer Center has licensed the Rosetta Resolver software system to investigate the clinical value of microarrays for assisting in cancer staging, the licensing partners said today.

The Florida-based center will use the technology for investigating the clinical value of oligonucleotide microarrays, according to a statement.

No further details were released.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.